Adefovir

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H12N5O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GQP90I798, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)- but generally known as adefovir, which bears US NIH Compound Identifier 60172. Adefovir most often comes in dipivoxil and pivoxil forms. European Medicines Agency schedules Adefovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05264MIG. The term ADEFOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ADEFOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adefovir under HS 29335995 and SITC 51576. As of Q4 2014, ADEFOVIR remains the US FDA Preferred Term for this commodity. Adefovir bears US NLM identifiers UMLS ID C0050175 and NCI Concept Code C61526. SMILES: C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O.